131 related articles for article (PubMed ID: 37387481)
1. Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies.
Jodele S; Mizuno K; Sabulski A; Vinks AA
Clin Pharmacol Ther; 2023 Sep; 114(3):511-514. PubMed ID: 37387481
[No Abstract] [Full Text] [Related]
2. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.
Vasu S; Wu H; Satoskar A; Puto M; Roddy J; Blum W; Klisovic R; Andritsos L; Hofmeister C; Benson DM; Efebera Y; Jaglowski S; Penza S; Cohen D; Devine S; Cataland S
Bone Marrow Transplant; 2016 Sep; 51(9):1241-4. PubMed ID: 27064689
[No Abstract] [Full Text] [Related]
3. Eculizumab was safe and effective in the management of transplant-associated thrombotic microangiopathy in a heart transplant recipient with concurrent COVID-19 infection.
Xu C; Wong V; Kurniawan A; Wilson S; Gopal B; Lawton PD
Intern Med J; 2023 Aug; 53(8):1506-1508. PubMed ID: 37599228
[No Abstract] [Full Text] [Related]
4. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab.
Bakhtar O; Thajudeen B; Braunhut BL; Yost SE; Bracamonte ER; Sussman AN; Kaplan B
Transplantation; 2014 Aug; 98(3):e17-8. PubMed ID: 25089339
[No Abstract] [Full Text] [Related]
5. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.
Gabr JB; Bilal H; Mirchia K; Perl A
J Investig Med High Impact Case Rep; 2020; 8():2324709620947266. PubMed ID: 32757799
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?
Fakhouri F; Frémeaux-Bacchi V
Nat Rev Nephrol; 2013 Sep; 9(9):495-6. PubMed ID: 23917793
[No Abstract] [Full Text] [Related]
7. Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report.
Safa K; Logan MS; Batal I; Gabardi S; Rennke HG; Abdi R
Clin Nephrol; 2015 Feb; 83(2):125-9. PubMed ID: 24495904
[TBL] [Abstract][Full Text] [Related]
8. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: A case report].
Rogier T; Gerfaud-Valentin M; Pouteil-Noble C; Taleb A; Guillet M; Noel A; Broussolle C; Sève P
Rev Med Interne; 2016 Oct; 37(10):701-704. PubMed ID: 26833144
[TBL] [Abstract][Full Text] [Related]
11. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy.
Peffault de Latour R; Xhaard A; Fremeaux-Bacchi V; Coppo P; Fischer AM; Helley D; Socié G
Br J Haematol; 2013 Apr; 161(2):279-80. PubMed ID: 23294015
[No Abstract] [Full Text] [Related]
12. Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment with Eculizumab.
Iqbal Z; Wood K; Carter V; Goodship TH; Brown AL; Sheerin NS
Transplant Proc; 2015 Sep; 47(7):2258-61. PubMed ID: 26361694
[TBL] [Abstract][Full Text] [Related]
13. The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.
Bjørkto MH; Barratt-Due A; Nordøy I; Dörje C; Galteland E; Lind A; Hilli A; Aukrust P; Mjøen G
BMC Infect Dis; 2021 Feb; 21(1):137. PubMed ID: 33526010
[TBL] [Abstract][Full Text] [Related]
14. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of eculizumab on thrombotic microangiopathies: another point of view.
Park SJ; Shin JI
Am J Kidney Dis; 2014 Jan; 63(1):166-7. PubMed ID: 24360227
[No Abstract] [Full Text] [Related]
16. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT.
Mizuno K; Dandoy CE; Teusink-Cross A; Davies SM; Vinks AA; Jodele S
Blood Adv; 2022 Mar; 6(5):1454-1463. PubMed ID: 35008105
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease.
Chonat S; Graciaa S; Shin HS; Newton JG; Quarmyne MO; Boudreaux J; Tang A; Zerra PE; Rollins MR; Josephson CD; Brown C; Joiner CH; Fasano RM; Stowell SR
Haematologica; 2020 Dec; 105(12):2887-2891. PubMed ID: 33256394
[No Abstract] [Full Text] [Related]
18. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.
Wilson CH; Brown AL; White SA; Goodship TH; Sheerin NS; Manas DM
Transplantation; 2011 Oct; 92(8):e42-3. PubMed ID: 21989273
[No Abstract] [Full Text] [Related]
19. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
Alhomoud M; Williams A; Magro C; Van Besien K; Vesole DH; Laurence J
Leuk Lymphoma; 2022 Feb; 63(2):473-477. PubMed ID: 34668824
[No Abstract] [Full Text] [Related]
20. In reply to 'Beneficial effect of eculizumab on thrombotic microangiopathies: another point of view'.
Schmidtko J; Peine S
Am J Kidney Dis; 2014 Jan; 63(1):167. PubMed ID: 24360228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
